TheraRadar
← Back
Data updated: Jun 28, 2026

PHARMACIA UPJOHN

Pharma

PHARMACIA UPJOHN is a pharmaceutical company focused on Immunology, Gastroenterology.

2000
Since
1
Drugs
-
Trials
0
New Drugs (2yr)
Modality:
1 Small Molecules

PHARMACIA UPJOHN's Key Drugs

PHARMACIA UPJOHN's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).

No active drugs

PHARMACIA UPJOHN's Recent FDA Approvals

New NDA/BLA approvals for PHARMACIA UPJOHN over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

PHARMACIA UPJOHN's Therapeutic Areas

PHARMACIA UPJOHN's approved drugs and pipeline span 2 therapeutic areas, led by Immunology and Gastroenterology, across 0 biologic and 1 small-molecule drug. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Immunology 50%
1 drugs
Gastroenterology 50%
1 drugs

PHARMACIA UPJOHN's Top Competitors

PHARMACIA UPJOHN's closest competitors by therapeutic-area and drug-target overlap include Johnson & Johnson, Bristol-Myers Squibb, and BAUSCH. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.

PHARMACIA UPJOHN Pipeline Snapshot

Active clinical trials for PHARMACIA UPJOHN across all therapeutic areas, from ClinicalTrials.gov.

No active pipeline data available

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • Top drug revenue breakdown
  • Drug-level revenue analysis

Trial Catalysts

  • Immunology pipeline focus
  • Phase 3 readout tracking

Patent Risk

  • Patent expiration timeline
  • Revenue at risk analysis

Compare Companies

  • Side-by-side pipeline analysis
  • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling